Drug Patents owned by Novartis Pharm

1. Drug name - AFINITOR DISPERZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide Mar, 2023

(5 months from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET, FOR SUSPENSION;ORAL Prescription
3MG TABLET, FOR SUSPENSION;ORAL Prescription
5MG TABLET, FOR SUSPENSION;ORAL Prescription

2. Drug name - TABRECTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(5 years from now)

US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(5 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(8 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(12 years from now)

CN101641093A NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

CN101641093B NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

CN103288833B NOVARTIS PHARM As Kinase Inhibitors And Triazine And Imidazo-Pyrimidine
Nov, 2027

(5 years from now)

CN103288833A NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

CN102083814B NOVARTIS PHARM 2-Fluorin-N-Methyl -4-[7 - (Quinolin - -6 - Base Methyl) Imidazole And [1, 2-B] [1, 2, 4] Triazine - -2 - Base] Salt Of Benzamide And The Relative Preparation Method Of
May, 2029

(6 years from now)

CN102083814A NOVARTIS PHARM Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)-Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
May, 2029

(6 years from now)

CN103936743A NOVARTIS PHARM 2-Fluoro-N-Methyl - -4-[7 - (-6 - Ylmethyl) Imidazo [1 2-B] [1 2 4] -2] Benzamide Salt And Preparation Method Thereof
May, 2029

(6 years from now)

CN103936743B NOVARTIS PHARM 2-Fluoro-N-Methyl - -4-[7 - (Quinolin - -6 - Ylmethyl) - Imidazo [1-B] [1, 2, 4] Triazin - -2 - Yl] Benzamide And Preparation Method Thereof
May, 2029

(6 years from now)

IN286624B NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

IN200901962P2 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP3034075B1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2497470A1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2099447B1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP3034075A1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2497470B1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2099447A1 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2497470B8 NOVARTIS PHARM Imidazotriazines And Imidazopyrimidines As Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2300455B1 NOVARTIS PHARM Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)- Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
May, 2029

(6 years from now)

EP2300455A2 NOVARTIS PHARM Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl)- Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide And Processes Related To Preparing The Same
May, 2029

(6 years from now)

EP3172209A1 NOVARTIS PHARM Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide
Jul, 2035

(12 years from now)

EP3172209B1 NOVARTIS PHARM Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same May, 2029

(6 years from now)

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.